Table 1—

Associations of demographic, epidemiological and clinical characteristics and therapy with QuantiFERON®-TB Gold in-tube (QFT-GIT)- and tuberculin skin test (TST)-positive results in subjects with rheumatic diseases: univariate analysis

TotalQFT-GIT positivep-value#TST positivep-value#
Total393 (100)52 (13.2)74 (18.8)
Sex0.030.09
 Male137 (34.9)25 (18.2)32 (23.4)
 Female256 (65.1)27 (10.5)42 (16.4)
BCG vaccinated0.10.009
 Yes16 (4.1)07 (9.5)
 No377 (95.9)52 (100.0)67 (90.5)
Birth/residence in countries at high prevalence of TB0.70.05
 Yes18 (4.6)2 (3.8)7 (9.5)
 No375 (95.4)50 (96.2)67 (90.5)
Age yrs0.0010.03
 ≤2945 (11.5)1 (2.2)2 (4.4)
 30–49129 (32.8)12 (9.3)25 (19.4)
 50–69167 (42.5)25 (15)35 (21.0)
 >7052 (13.2)14 (26.9)12 (23.1)
Chest radiograph patterns0.080.009
 No lesions of past TB80 (20.3)6 (7.5)14 (17.5)
 Lesions of past TB41 (10.5)9 (22.0)15 (36.5)
 Other patterns272 (69.2)37 (13.5)45 (16.5)
Close contact to patients with sputum-positive TB0.020.02
 Yes7 (1.8)3 (5.7)4 (5.4)
 No386 (98.2)49 (94.3)70 (94.6)
Diagnosis0.30.4
 Rheumatoid arthritis201 (51.1)27 (13.4)35 (17.4)
 Psoriasic arthritis94 (23.9)23 (24.5)16 (17)
 Ankilosing spondilytis58 (14.8)5 (8.6)11 (19)
 Other40 (10.2)4 (10)5 (12.5)
Therapy+
 No therapy in last 3 months83 (21.1)13 (25)22 (29.7)
 DMARDs75 (19.1)12 (23.1)0.919 (25.7)0.8
 DMARDs + steroids106 (27)13 (25)0.522 (29.7)0.3
 Steroids34 (8.7)2 (3.8)0.11 (1.3)0.004
 TNF-α inhibitors30 (7.6)6 (11.5)0.24 (5.4)0.1
 TNF-α inhibitors + DMARDs25 (6.4)4 (7.6)0.94 (5.4)0.2
 TNF-α inhibitors + steroids4 (1)00.300.2
 TNF-α inhibitors + DMARDs + steroids36 (9.2)2 (3.8)0.12 (2.7)0.009
  • Data are expressed as n (%), unless otherwise stated. BCG: bacillus Calmette–Guérin; TB: tuberculosis; DMARD: disease-modifying antirheumatic drugs; TNF-α: tumour necrosis factor-α. #: by Chi-squared test or Fisher's exact test as appropriate. : includes uveitis, Crohn's disease, juvenile chronic arthritis, undifferentiated spondyloarthropathy (n = 3 for each); Behçet's disease, Still's disease, enteritis, temporal arteritis, scleroderma, seronegative oligoarthritis, seronegative spondyloarthritis, ulcerative colitis (n = 2 for each); systemic lupus erythematosus, systemic sclerosis, erythema nodosum, Wegener's granulomatosis, polymyalgia syndrome, sarcoidosis, reactive arthritis, psoriasis, myopathy of unclear origin, familial mediterranean fever, sacroileitis and seronegative spondyloarthritis with Castleman's disease (n = 1 for each). +: p-values were derived from comparison of the test results in patients with each single regimen and those of untreated patients. QFT-GIT from Cellestis Limited, Carnegie, Australia.